IGI Logo

Cadila Healthcare is currently trading at Rs. 474.10, up by 12.85 points or 2.79% from its previous closing of Rs. 461.25 on the BSE.

The scrip opened at Rs. 464.15 and has touched a high and low of Rs. 475.80 and Rs. 462.95 respectively. So far 152035 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 509.35 on 15-Jan-2021 and a 52 week low of Rs. 318.10 on 08-May-2020.

Last one week high and low of the scrip stood at Rs. 475.80 and Rs. 434.35 respectively. The current market cap of the company is Rs. 48525.40 crore.

The promoters holding in the company stood at 74.88%, while Institutions and Non-Institutions held 16.96% and 7.97% respectively.

Zydus Cadila has received final approval from the USFDA to market Macitentan Tablets, 10 mg (US RLD: Opsumit Tablets). Macitentan is used to manage the symptoms of pulmonary arterial hypertension. Macitentan is in a class of medications called endothelin receptor antagonists. It works by stopping the action of endothelin, a natural substance that causes blood vessels to narrow and prevents normal blood flow in people who have Pulmonary Arterial Hypertension.

According to the USFDA letter, Zydus was one of the first ANDA applicants to submit a substantially complete ANDA with a paragraph IV certification for Macitentan Tablets, 10 mg. Therefore, with this approval, Zydus is eligible for 180 days of shared generic drug exclusivity for Macitentan Tablets, 10 mg. The group now has 314 approvals and has so far filed over 400 ANDAs since the commencement of the filing process in FY 2003-04.

Cadila Healthcare is an India-based pharmaceutical company. The company's subsidiaries include Zydus Wellness, Liva Pharmaceuticals, Biochem Pharmaceutical Industries, Zydus Technologies, German Remedies, Dialforhealth India, Dialforhealth Unity and Dialforhealth Greencross, among others.